Fycompa (perampanel) Tablets
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2013
WARNINGS AND PRECAUTIONS
Psychiatric and Behavioral Reactions
- Homicidal ideation and/or threat were exhibited in 0.1% of 4,368 perampanel treated patients in controlled and open label studies, including non-epilepsy studies.